You eat carefully, you move, and the weight stays where it is. If you have been told PCOS is the reason, that is roughly half right, and it is worth knowing which half.

Polycystic ovary syndrome does change how the body handles glucose, and that change is measurable. What it does not come with is a diet plan. Most PCOS weight-loss advice in circulation (the carbohydrate rules, the keto warnings, the meal-timing schedules) runs well ahead of what has been tested in women with PCOS.

What follows is the part the evidence carries, the part it does not, and what that leaves worth doing.

• Insulin sensitivity is reduced by about 27% in PCOS independent of BMI. A normal weight is not evidence that glucose handling is fine.
• Insulin resistance and weight gain travel together and reinforce one another. Neither is a switch that controls the other.
• The 2023 international guideline, endorsed by more than 30 professional societies, names no single dietary pattern over another, because no trial has tested one against another by diagnostic presentation.
• Indian data from the 2024 JAMA Network Open study found 43.2% obesity, 91.9% dyslipidaemia and 32.9% metabolic fatty liver in women with PCOS. PCOS is a cardiometabolic condition, not only a reproductive one.
• Visceral fat, not the diagnostic label, tracks most closely with insulin resistance in PCOS. A waist measurement is a more informative starting point than a set of food rules.
• The 2023 guideline recommends screening every woman with PCOS for depression and anxiety. Screening is a clinical act, and it is reasonable to ask for it.

Insulin resistance is the most consistent metabolic finding in PCOS, and it is not a consequence of body weight alone. A systematic review and meta-analysis of clamp studies, the reference method for measuring insulin action, found insulin sensitivity reduced by around 27% in women with PCOS compared with controls, independent of BMI.

That finding matters because it means a slim woman with PCOS can carry the same underlying problem as a woman with obesity, and that a normal weight is not evidence that glucose handling is fine.

Insulin resistance appears across every diagnostic combination that produces a PCOS label, at differing prevalence. Body-composition studies have repeatedly found visceral fat correlating with insulin resistance across all of them, pointing at where fat sits rather than at which label a woman was given.

What none of that licenses is the familiar claim that insulin resistance flips the body into a fat-storage mode ordinary eating cannot overcome. Insulin resistance and weight gain travel together and reinforce one another. Describing one as a switch that operates the other is a simplification the measurement literature does not carry.

The Indian national community study of PCOS, published in JAMA Network Open in 2024, did more than count cases. Among the Indian women it identified with PCOS:

• 43.2% had obesity
• 91.9% had dyslipidaemia
• 32.9% had metabolic dysfunction-associated fatty liver disease

Those figures are not stratified by presentation, so they describe the diagnosis as a whole rather than any one version of it.

Read alongside the insulin findings, that is the case for treating PCOS as a cardiometabolic condition rather than only a reproductive one. Current guidance asks for glucose, lipid and blood-pressure screening in every woman with PCOS regardless of how she presents.

An oral glucose tolerance test is recommended at the point of diagnosis rather than held back until symptoms appear. Repeat glycaemic assessment is then suggested every one to three years according to individual risk.

None of that is weight-dependent, which is the part most often missed by women who were told their PCOS was mild because their weight was normal.

Most PCOS content gets this section wrong, and the correction is uncomfortable. The 2023 international guideline, endorsed by more than 30 professional societies, recommends lifestyle intervention for all women with PCOS and then states plainly that no single dietary pattern is recommended over any other, and no single exercise modality over any other. What it names instead is a sustained energy deficit where weight loss is indicated, prevention of further weight gain, and minimising weight stigma.

The reason is an absence rather than a negative result. No randomised dietary or lifestyle trial in PCOS has stratified or randomised participants by their diagnostic presentation and reported outcomes accordingly. Trials compare women with PCOS against controls, or test one diet against another within PCOS as a single pooled group. Rules of the form "PCOS means low glycaemic carbohydrates" or "PCOS means avoiding keto" are extrapolated from cross-sectional metabolic differences, not from a trial that tested them.

That does not make the everyday version of the advice harmful. Choosing whole grains and pulses over refined flour and sugary drinks is reasonable general nutrition, and it is what most Indian kitchens already do well. It is not a PCOS-specific prescription, and it should not be sold as one.

Indian practice documents add one caution worth repeating: unnecessary calorie restriction in lean PCOS is discouraged, with weight maintenance and metabolic health as the targets instead. Whether a restrictive pattern of any kind suits you is a question for a registered dietitian or a registered medical practitioner who can see your cycles, your thyroid status and your history.

The guideline recommends physical activity for every woman with PCOS, either exercise alone or as part of a multicomponent programme combining diet, activity and behavioural support. It does not name a modality, a frequency or a session length as superior. Walking, resistance work and structured classes all sit inside that recommendation, and the one that continues for years is the one that counts.

Sleep quality and stress are commonly named as PCOS weight barriers. The honest position is that the guideline treats behavioural support as part of a multicomponent programme rather than as a separate intervention with its own evidence base in PCOS.

Mental health carries a firmer recommendation than the diet advice does. Pooled analyses put depression prevalence in PCOS at around 34.8% and anxiety disorders at 16.9%. The 2023 guideline recommends screening every adult and adolescent with PCOS for both, with no distinction by presentation.

Screening is a clinical act with a defined follow-up attached to it, and it is reasonable to ask for it.

Any decision here belongs to a prescriber after an examination, and nothing below is a reason to start, stop or change anything.

Metformin is recommended primarily for metabolic and anthropometric features in adults with a BMI of 25 kg/m² or above, with conditional consideration below that. The guideline grades the underlying evidence as low to very low certainty.

Combined oral contraceptives are the first-line pharmacological option for menstrual irregularity and androgen-related symptoms in adults.

Inositol is where the gap between marketing and evidence is widest. A systematic review and meta-analysis prepared for the 2023 guideline update found the evidence inconsistent and of very low certainty, and concluded that no specific preparation, dose or combination can currently be recommended. Guidance favours metformin over inositol for central adiposity and for hirsutism. Supplements are not neutral by default, and a supportive tool with very low certainty evidence behind it is still an expense and still worth discussing before buying.

The most useful thing PCOS tells you about weight is that the metabolic side deserves measuring rather than assuming, and that a normal number on the scale settles less than it appears to.

Since visceral fat rather than the diagnostic label tracks most closely with insulin resistance in PCOS, a waist-to-hip measurement is a more informative starting point than another set of food rules. A consultation with a registered medical practitioner is what turns any of it into a plan that fits your cycles, your labs and your life.

PCOS and weight that is not moving despite genuine effort? A Voy clinician can look at your labs, your cycles and your full metabolic picture together. Book a consultation.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.